TScan Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2025
Filed with the SEC on Nov 12, 2025 and accepted by EDGAR at Nov 12, 2025, 07:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-07-01 to 2025-09-30 | $2.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2025-01-01 to 2025-09-30 | $7.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2025-07-01 to 2025-09-30 | $31.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2025-01-01 to 2025-09-30 | $94.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-07-01 to 2025-09-30 | −$37.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2025-01-01 to 2025-09-30 | −$112.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-07-01 to 2025-09-30 | $699.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2025-01-01 to 2025-09-30 | $2.1m | us-gaap:InterestExpense |
| Net income | 3 months2025-07-01 to 2025-09-30 | −$35.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months2025-01-01 to 2025-09-30 | −$106.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-07-01 to 2025-09-30 | −$0.28 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2025-01-01 to 2025-09-30 | −$0.82 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-07-01 to 2025-09-30 | −$0.28 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2025-01-01 to 2025-09-30 | −$0.82 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-07-01 to 2025-09-30 | 129,835,938 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2025-01-01 to 2025-09-30 | 129,748,897 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2025-01-01 to 2025-09-30 | −$103.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2025-01-01 to 2025-09-30 | $4.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-09-30 | $169.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-09-30 | $188.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-09-30 | $262.2m | us-gaap:Assets |
| Current liabilities | At period end2025-09-30 | $29.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-09-30 | $118.2m | us-gaap:Liabilities |
| Long-term debt | At period end2025-09-30 | $32.4m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2025-09-30 | $144.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-25-275933. Last ingested by Listed: Oct 26, 2026, 08:08 ET. Listed shows no prices and gives no investment advice.